Aptevo Therapeutics Inc APVO
News
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds
Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML